• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Following a Delayed Launch, Bristol Myers Squibb's Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights

Spherix's new launch tracking service will further monitor details of Zeposia's uptake over 18 months and benchmark key metrics against historical launches, including Genentech's Ocrevus and Novartis' Mayzent

Invest In Intelligence That Delivers

News provided by

Spherix Global Insights

Sep 16, 2020, 07:30 ET

Share this article

Share this article


EXTON, Pa., Sept. 16, 2020 /PRNewswire/ -- With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, oral DMT class share has increased slightly over the past year, according to the most recent report included in Spherix's RealTime Dynamix™: Multiple Sclerosis (US) service. The report, which collected the responses of 99 neurologists in the United States surveyed between July 17th and August 4th, finds that Novartis' Mayzent and Biogen's Vumerity have experienced modest share growth over the past quarter while uptake of recently launched Bristol Myers Squibb's Zeposia has just begun.

As the third-to-market S1P receptor modulator, Zeposia shows early signs of promise in MS. While COVID-19 initially delayed Zeposia's launch, the DMT is now on the market and has amassed a prescriber base of approximately 20% of surveyed physicians within the first two months of availability. Neurologists project Zeposia share to rival that of Mayzent within the next six months. Already, more physicians prefer Zeposia than Mayzent among the oral DMTs, although Novartis' Gilenya is still the most preferred S1P receptor modulator DMT. Many neurologists are optimistic about the Zeposia onboarding process – two in five believe that the lack of first-dose observation requirement will increase their willingness to prescribe, and more than one-third anticipate that Zeposia onboarding will be easier than that for Gilenya or Mayzent.

However, these high-efficacy oral DMTs are not immune to impacts related to COVID-19. Half of surveyed physicians specified changes in the way they manage their MS patients due to the pandemic, including a temporary reversion to more conservative practices and a preference for DMTs with the strongest safety profiles. Among the sizeable minority of neurologists who have decreased their use of Gilenya or Mayzent over the past three months, 57% and 73%, respectively, indicate that COVID-19 had a high influence on the reductions in use.

Furthermore, the coronavirus outbreak has hindered Zeposia uptake by limiting the frequency of detailing visits from sales representatives. Nearly three-quarters of surveyed neurologists have never had contact with a Zeposia sales representative, and even fewer neurologists have received an in-person detail. Highlighting the power that personal interaction (whether in person or virtual) can have on new brand uptake, more than half of neurologists detailed on Zeposia with in the past month are current prescribers versus only 7% of those not recently detailed.

Neurologists are most willing to use Zeposia in relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS), or transitioning patients, consistent with Bristol Myers Squibb's positioning efforts and current patterns of use. However, the brand must contend with substantial competition within the relapsing MS space, both from other high-efficacy oral DMTs (including S1P receptor modulators) and especially from Ocrevus. While many neurologists believe that oral Zeposia outperforms intravenous Ocrevus on administration, a large proportion also believe that the former is at a disadvantage to the latter on efficacy in relapsing forms of MS and metrics related to market tenure (such as known safety profile, clinical data support, and overall familiarity/comfort).

Despite the mechanistic similarities between Zeposia and Mayzent, use patterns for Zeposia are already quite distinct: Zeposia derives a much higher percentage of use from RRMS, while Mayzent, as a result of Novartis' positioning efforts related to the DMT's novel EXPAND trial design, is more frequently prescribed to active SPMS patients. Mayzent is a common alternative treatment to Zeposia, although neurologists expect Gilenya to suffer more from Zeposia's share growth. Indeed, beyond issues related to time on market, use of an alternative S1P receptor modulator is currently among the most commonly cited barriers to Zeposia use, especially among non-users; should this attitude remain consistent over the next year, Zeposia uptake could suffer.

In order to more deeply assess the progression of Zeposia's launch, a new service starting in Q4 2020, Launch Dynamix™: Zeposia in Multiple Sclerosis (US), will further delve into awareness, trial, and use patterns as well as neurologist perceptions related to the agent's value within the competitive MS space. Furthermore, the service will benchmark Zeposia launch metrics to other recent launches in MS, including Ocrevus, EMD Serono's Mavenclad, and Mayzent. In addition to Zeposia, Spherix will track other upcoming branded launches in MS, including Biogen's Vumerity, Novartis' Kesimpta (beginning in Q4 2020), and, if approved in Q1 2020, Janssen's ponesimod.

In parallel, future waves of the RealTime Dynamix™: Multiple Sclerosis (US) service will continue to provide a comprehensive view of the impact of recent launches, market events, and pipeline developments on the evolution of the MS market. Looking even further ahead, Spherix recently added three emerging Bruton's tyrosine kinase (BTK) inhibitors, EMD Serono's evobrutinib, Sanofi/Principia Biopharma's tolebrutinib (SAR442168), and Genentech's fenebrutinib (RG7845), to their pipeline assessments in the RealTime Dynamix™ service.

As with the ongoing battle between the S1P receptor modulators, unique individual characteristics of these BTK inhibitors (coupled with careful positioning efforts) will determine neurologist preference and overall success within the MS market.

About RealTime Dynamix™
RealTime Dynamix™: Multiple Sclerosis (US) is an independent service providing strategic guidance through rapid and comprehensive quarterly reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The next quarterly report publishes in December.

Parallel services, RealTime Dynamix™: Multiple Sclerosis (EU) and RealTime Dynamix™: Multiple Sclerosis (Canada) track the evolution of multiple sclerosis market in Europe and Canada on a semiannual basis.

About Launch Dynamix™  
Launch Dynamix™ is an independent, subscription-based service that provides quarterly trending of relevant launch metrics for new products and benchmarking to other recently launched products.

About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:
Kristen Henn, Business Development Manager
Email: [email protected]
www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Related Links

http://www.spherixglobalinsights.com

Modal title

Also from this source

Spherix Global Insights Announces Special Coverage of Amgen's Amjevita Launch, Tracking Uptake and Perceptions of the First Commercially-available Biosimilar to AbbVie's Humira

Spherix Global Insights Announces Special Coverage of Amgen's Amjevita Launch, Tracking Uptake and Perceptions of the First Commercially-available Biosimilar to AbbVie's Humira


Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical's Lupkynis and GSK's Benlysta, According to Spherix Global Insights

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Biotechnology
  • New Products & Services
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.